ResMed Inc (RMD) general counsel reports 50-share insider stock sale

Rhea-AI Filing Summary

ResMed Inc.'s Global General Counsel and Secretary reported a small stock sale in a Form 4 filing. On 01/02/2026, the officer sold 50 shares of ResMed common stock at a price of $241.75 per share. After this transaction, the officer beneficially owned 9,741 shares, held directly.

The filing notes that this transaction was conducted under a pre-established Rule 10b5-1 trading plan that was adopted on February 28, 2025. Such plans allow insiders to sell shares according to predetermined instructions, helping separate routine portfolio management from the timing of any company news.

Insider Trade Summary

Net Seller: 50 shares ($12,088)

Net Sell 1 txn

Insider Rider Michael J

Role Global General Counsel

Sold 50 shs ($12K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	50	$241.75	$12K

Holdings After Transaction: ResMed Common Stock — 9,741 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rider Michael J

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	01/02/2026		S(1)		50	D	$241.75	9,741	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

	/s/ Michael J. Rider, Global General Counsel and Secretary	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed Inc (RMD) report in this Form 4?

The Global General Counsel and Secretary of ResMed Inc. reported selling 50 shares of ResMed common stock on 01/02/2026 at a price of $241.75 per share, according to the Form 4.

How many ResMed (RMD) shares does the reporting person own after this transaction?

Following the reported sale, the officer beneficially owned 9,741 shares of ResMed common stock, held in direct ownership.

Who is the insider involved in this ResMed (RMD) Form 4 filing and what is their role?

The reporting person is an officer of ResMed Inc., serving as Global General Counsel and Secretary, as indicated in the Form 4.

Was the ResMed (RMD) insider sale made under a Rule 10b5-1 trading plan?

Yes. The explanation states that the transaction was conducted under a Rule 10b5-1 plan that was adopted February 28, 2025.

What type of security was involved in this ResMed (RMD) insider transaction?

The transaction involved ResMed common stock, as listed in Table I of the Form 4.

Is this ResMed (RMD) Form 4 filed by one reporting person or a group?

The Form 4 is marked as Form filed by One Reporting Person, indicating it relates to a single insider.